ARQT SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 4, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 6, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 25, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oct 28, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update

Nov 4, 2026

8-K

Arcutis Biotherapeutics Appoints Rob Scott, MD to Board of Directors

Oct 28, 2026

8-K

Arcutis Biotherapeutics Reports Q2 2026 Financial Results and Raises Full-Year Sales Guidance

Aug 5, 2026

8-K

Arcutis Biotherapeutics Appoints Chris Peetz to Board of Directors

Jul 16, 2026

8-K

Arcutis Biotherapeutics, Inc. Announces Results of 2026 Annual Meeting and Updates Director Compensation Program

Jun 9, 2026

8-K

Arcutis Biotherapeutics Reports Q1 2026 Financial Results and Business Updates

May 6, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

November 2026 ATM | Offering amount: $200,000,000 | Bank: TD Cowen

Nov 4, 2026

424B5

15,789,474 Shares

Mar 1, 2024

424B5

Common Stock

Feb 28, 2024

424B5

Shares of our common stock having an aggregate offering price of up to $100,000,000.

Feb 8, 2024

424B5

32,500,000 Shares of Common Stock

Oct 23, 2023

424B5

Common Stock

Oct 19, 2023

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Apr 21, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 25, 2026

S-3ASR

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Feb 25, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 25, 2025

S-8

Registration

Feb 27, 2024

SC TO-I/A

Options to Purchase Common Stock, Par Value $0.0001 Per Share

Feb 15, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 21, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 21, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 26, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 26, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Matsuda Masaru (Reporting)

Nov 4, 2026

Lisicki Robert (Reporting)

Nov 4, 2026

Burnett Patrick (Reporting)

Nov 4, 2026

3/A

SCOTT ROBERT A (Reporting)

Nov 4, 2026

Watanabe Todd (Reporting)

Nov 4, 2026

144

Form 144 - Report of proposed sale of securities

Nov 4, 2026

Other

TYPE

HEADLINE

FILED AT

LETTER

Form UPLOAD - SEC-generated letter

Dec 2, 2025

CORRESP

Form CORRESP - Correspondence

Oct 10, 2025

LETTER

Form UPLOAD - SEC-generated letter

Sep 15, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Feb 9, 2024

CORRESP

Form CORRESP - Correspondence

Feb 6, 2024

LETTER

Form UPLOAD - SEC-generated letter

Feb 5, 2024

Arcutis Biotherapeutics, Inc. ARQT · SEC Filings